Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

ClinicalTrials.gov ID: NCT03633617

Public ClinicalTrials.gov record NCT03633617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Study identification

NCT ID
NCT03633617
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
321 participants

Conditions and interventions

Interventions

  • Dupilumab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 23, 2018
Primary completion
Sep 8, 2021
Completion
Jun 6, 2022
Last update posted
Jun 27, 2023

2018 – 2022

United States locations

U.S. sites
62
U.S. states
27
U.S. cities
57
Facility City State ZIP Site status
Regeneron Study Site Phoenix Arizona 85016
Regeneron Study Site Scottsdale Arizona 85259
Regeneron Study Site Little Rock Arkansas 72202
Regeneron Study Site La Jolla California 92037
Regeneron Study Site Los Angeles California 90025
Regeneron Study Site Mountain View California 94305
Regeneron Study Site Orange California 92868
Regeneron Study Site Rolling Hills Estates California 90274
Regeneron Study Site San Diego California 92123
Regeneron Study Site Aurora Colorado 80045
Regeneron Study Site Aurora Colorado 80220
Regeneron Study Site Colorado Springs Colorado 80907
Regeneron Study Site Lone Tree Colorado 80124
Regeneron Study Site Bristol Connecticut 06010
Regeneron Study Site Miami Florida 33156
Regeneron Study Site St. Petersburg Florida 33701
Regeneron Study Site Boise Idaho 83706
Regeneron Study Site Idaho Falls Idaho 83404
Regeneron Study Site #1 Chicago Illinois 60611
Regeneron Study Site #2 Chicago Illinois 60611
Regeneron Study Site Park Ridge Illinois 60068
Regeneron Study Site Urbana Illinois 61801
Regeneron Study Site Indianapolis Indiana 46202
Regeneron Study Site Clive Iowa 50325
Regeneron Study Site Iowa City Iowa 52242
Regeneron Study Site Topeka Kansas 66606
Regeneron Study Site Hagerstown Maryland 21742
Regeneron Study Site Boston Massachusetts 02111
Regeneron Study Site Worcester Massachusetts 01655
Regeneron Study Site Ann Arbor Michigan 48109
Regeneron Study Site Chesterfield Michigan 48047
Regeneron Study Site Plymouth Minnesota 55446
Regeneron Study Site Rochester Minnesota 55905
Regeneron Study Site Lincoln Nebraska 68505
Regeneron Study Site Omaha Nebraska 68130
Regeneron Study Site Great Neck New York 11021
Regeneron Study Site Great Neck New York 11023
Regeneron Study Site New York New York 10016
Regeneron Study Site New York New York 10029
Regeneron Study Site New York New York 10032
Regeneron Study Site The Bronx New York 10461
Regeneron Study Site Chapel Hill North Carolina 27599
Regeneron Study Site Cincinnati Ohio 45229
Regeneron Study Site Dayton Ohio 45415
Regeneron Study Site Dublin Ohio 43016
Regeneron Study Site Mentor Ohio 44060
Regeneron Study Site Hershey Pennsylvania 17033
Regeneron Study Site Philadelphia Pennsylvania 19104
Regeneron Study Site Charleston South Carolina 29425
Regeneron Study Site Greenville South Carolina 29615
Regeneron Study Site Johnson City Tennessee 37604
Regeneron Study Site Memphis Tennessee 38103
Regeneron Study Site Dallas Texas 75207
Regeneron Study Site Fort Worth Texas 76104
Regeneron Study Site Garland Texas 75044
Regeneron Study Site Houston Texas 77030
Regeneron Study Site San Antonio Texas 78229
Regeneron Study Site Salt Lake City Utah 84132
Regeneron Study Site Charlottesville Virginia 22903
Regeneron Study Site Roanoke Virginia 24013
Regeneron Study Site Seattle Washington 98115
Regeneron Study Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03633617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 27, 2023 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03633617 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →